Skip Nav Destination
Issues
1 June 2018
-
Cover Image
Cover Image
ABOUT THE COVER
This study, by Park and colleagues (beginning on page 935), demonstrates the anti-cancer effect of quinacrine (QNC) via a novel pathway through the elimination of check point kinase 1/2 (Chk1/2) under p53 inactivated conditions. The cover image shows hematoxylin and eosin (H&E) staining of the Villin-Cre;p53+/LSL-R172H mouse intestine obtained from the QNC-injected mouse. In contrast to invasive or diffuse cancer cells found in the control group of mice, only overgrown epithelial cells were detected in QNC-injected mouse tissues. These results show QNC treatment displayed anti-tumor effects in a Villin-Cre;p53+/LSL-R172H intestinal cancer mouse model system and strongly support the notion that QNC would be a plausible treatment strategy for p53 impaired cancers. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1541-7786
EISSN 1557-3125
Molecular Cancer Research
Table of Contents
Highlights
Cell Cycle and Senescence
Cell Death and Survival
Chromatin, Epigenetics, and RNA Regulation
D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant–Induced MIR148A Promoter Methylation
Tie Li; Christopher D. Cox; Byram H. Ozer; Nhung T. Nguyen; HuyTram N. Nguyen; Thomas J. Lai; Sichen Li; Fei Liu; Harley I. Kornblum; Linda M. Liau; Phioanh L. Nghiemphu; Timothy F. Cloughesy; Albert Lai
DNA Damage and Repair
Metabolism
Genomics
Oncogenes and Tumor Suppressors
Author Choice
USP28 Deficiency Promotes Breast and Liver Carcinogenesis as well as Tumor Angiogenesis in a HIF-independent Manner
Kati Richter; Teija Paakkola; Daniela Mennerich; Kateryna Kubaichuk; Anja Konzack; Heidi Ali-Kippari; Nina Kozlova; Peppi Koivunen; Kirsi-Maria Haapasaari; Arja Jukkola-Vuorinen; Hanna-Riikka Teppo; Elitsa Y. Dimova; Risto Bloigu; Zoltan Szabo; Risto Kerkelä; Thomas Kietzmann
Signal Transduction
Tumor Microenvironment and Immunobiology
ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer
Akimitsu Yamada; Masayuki Nagahashi; Tomoyoshi Aoyagi; Wei-Ching Huang; Santiago Lima; Nitai C. Hait; Aparna Maiti; Kumiko Kida; Krista P. Terracina; Hiroshi Miyazaki; Takashi Ishikawa; Itaru Endo; Michael R. Waters; Qianya Qi; Li Yan; Sheldon Milstien; Sarah Spiegel; Kazuaki Takabe
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.